Understanding how lung cancer develops and interacts with the immune system
Official title: Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development
Funded at University of Tx Md Anderson Can Ctr · NIH-11135449 · Data updated 2026-11-12
This research aims to understand the very first steps of lung adenocarcinoma development and how it interacts with the body's immune system.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $435,096 |
| NIH project number | 5U01CA264583-04 |
| Project ID | NIH-11135449 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with lung adenocarcinoma, especially those diagnosed at early stages, or individuals at high risk for the disease, could eventually benefit from this research.
✕Less likely to help
Patients with advanced lung cancer or other cancer types may not directly benefit from this specific early-stage development research.
What this research studies
Lung adenocarcinoma is a common and serious type of lung cancer, and while early detection is improving, we still don't fully understand what causes it to start in a specific area of the lung. This project looks closely at how different cells in the lung, including immune cells, change and interact over time and space as lung cancer begins to form. By studying these early changes in human samples, we hope to uncover the key events that drive the disease. This deeper understanding could help us find new ways to stop lung cancer before it becomes advanced.
Why it matters
Potential benefit: If successful, this work could lead to new strategies for early detection and prevention of lung adenocarcinoma, potentially improving outcomes for many patients.
How similar studies have gone: While preliminary efforts have shown promising insights into cellular changes, this project aims for a novel, more comprehensive understanding of the spatial and temporal co-evolution of tumor and immune cells in early lung cancer.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Kadara, Humam — University of Tx Md Anderson Can Ctr
- Study coordinator: Kadara, Humam
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.